Speakers: Lixia Yao, Polygon Health Analytics LLC; Aaron Mackey, Lokavant; Ying Li, Regeneron Pharmaceuticals, Inc.; Daisuke Goto, Organon & Co.; Star Chen, Merck & Co.
Organizers: Lixia Yao - Founder & CEO, Polygon Health Analytics LLC
Date: 2024-10-25
Time: 8:30-12:00 Pacific Time
Registration fee: Free
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-10-24  (it will close sooner if the seating cap is reached)

About the Topic

Real-world data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources, and Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. In this workshop, we delve into the transformative power of RWD and RWE in the pharmaceutical industry, which may transform every facet of the pharma industry from discovery to marketing. 

The following topics will be covered:

• Definitions, sources, and implications of RWD and RWE in today’s healthcare landscape. 
• RWD and RWE for drug discovery, highlighting how RWD can identify new therapeutic targets and accelerate new drug discovery
• The role of RWD in clinical development, including designing innovative trials, enhancing patient recruitment, and improving outcomes
• Health Economics and Outcome Research (HEOR), demonstrating the potential of RWD/RWE in cost-effectiveness analysis, budget impact analysis, and health technology assessment
• Strategic utilization of RWD in pharma marketing, discussing how it can inform strategies, support product positioning, and provide insights into market dynamics
• FDA's approaches on RWD and RWE for drug approval and regulation